Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML Academic Article uri icon

Overview

MeSH Major

  • Enzyme Inhibitors
  • Isocitrate Dehydrogenase
  • Leukemia, Myeloid, Acute

abstract

  • In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission. (Funded by Agios Pharmaceuticals; ClinicalTrials.gov number, NCT02074839 .).

authors

publication date

  • June 21, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1716984

PubMed ID

  • 29860938

Additional Document Info

start page

  • 2386

end page

  • 2398

volume

  • 378

number

  • 25